Last updated: February 19, 2026
Alinia (nitazoxanide) is an antiparasitic and antiviral medication. Its primary approved indication in the United States is for the treatment of diarrhea caused by the protozoa Cryptosporidium parvum and Giardia lamblia in immunocompetent individuals aged 12 years and older.
What is Alinia's Current Market Position?
Alinia is marketed by CME Pharmaceutical Services, Inc. in the United States. Its market position is characterized by a defined therapeutic niche, a stable but mature demand profile, and competition from generic formulations and alternative treatments.
Key Market Indicators for Alinia
- Approved Indications: Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia in individuals 12 years and older.
- Dosage Forms: Oral tablet (500 mg), oral suspension (100 mg/5 mL) [1].
- Target Patient Population: Immunocompetent individuals experiencing specific protozoal infections.
- Market Entry: Approved by the U.S. Food and Drug Administration (FDA) in 2004 [1].
- Competition: Generic versions of nitazoxanide are available, impacting brand pricing and market share. Other treatment options for giardiasis and cryptosporidiosis exist, though Alinia is a primary choice for specific patient groups.
What is Alinia's Clinical Utility and Demand Drivers?
Alinia's clinical utility is centered on its efficacy against two common gastrointestinal protozoal pathogens. Demand is driven by the prevalence of these infections, particularly in specific demographic groups and geographic regions.
Factors Influencing Alinia Demand
- Prevalence of Cryptosporidium and Giardia Infections: These protozoa are globally distributed and are common causes of diarrheal illness, especially in areas with poor sanitation and contaminated water sources.
- Giardia lamblia is one of the most common causes of foodborne illness in the United States [2].
- Cryptosporidium infections are also a significant public health concern, particularly outbreaks linked to recreational water exposure [3].
- Traveler's Diarrhea: Individuals traveling to regions where these parasites are endemic are at increased risk, contributing to demand.
- Pediatric Use (Off-Label Considerations): While approved for ages 12 and above, off-label use in younger children for these indications is a consideration for some prescribers, though not formally reflected in approved market data.
- Healthcare Provider Prescribing Patterns: The established efficacy and safety profile of Alinia contribute to its continued use by physicians for its approved indications.
What is the Competitive Landscape for Alinia?
The competitive landscape for Alinia includes direct competition from generic nitazoxanide and indirect competition from alternative treatments for the conditions it addresses.
Competitive Factors
- Generic Nitazoxanide: The availability of generic versions of nitazoxanide significantly influences Alinia's market share and pricing power. Generic entry typically leads to price erosion for the branded product.
- Alternative Treatments for Giardiasis:
- Metronidazole
- Tinidazole
- Furazolidone (less commonly used due to side effects and availability)
- Alternative Treatments for Cryptosporidiosis (Immunocompetent): While Alinia is a primary treatment, supportive care such as hydration is also crucial. For immunocompromised patients, management is more complex and may involve other agents.
- Emerging Therapies: Research into new antiparasitic or antiviral agents could potentially introduce new competitive threats in the future, though significant new entrants for these specific indications are not currently prominent.
What is Alinia's Patent and Exclusivity Status?
The patent and exclusivity landscape for Alinia is critical for understanding its commercial lifecycle and the impact of generic competition.
Patent and Exclusivity Details
- Original Patents: Original composition of matter patents and formulation patents for nitazoxanide have expired.
- FDA Exclusivity: The initial FDA approval in 2004 would have been accompanied by various forms of regulatory exclusivity (e.g., New Chemical Entity exclusivity), which have also expired.
- Generic Entry: The expiration of key patents and regulatory exclusivities has paved the way for generic manufacturers to enter the market. This has led to a substantial increase in the number of nitazoxanide products available at lower price points.
- Orange Book Data: The FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (Orange Book) lists approved drugs and their patent and exclusivity information. Nitazoxanide is listed with multiple generic approvals, indicating the absence of current market exclusivity for the branded product [4].
What is Alinia's Financial Trajectory and Market Value?
Alinia's financial trajectory has been shaped by its initial market launch, subsequent growth driven by its therapeutic utility, and the inevitable decline in revenue and market share following generic entry.
Financial Performance Overview
- Peak Sales: While precise peak sales figures for branded Alinia are not readily available in public financial reports of its marketer, CME Pharmaceutical Services, Inc. (a subsidiary of Silvergate Pharmaceuticals), the typical trajectory for branded drugs post-generic entry suggests a significant decline from peak performance.
- Revenue Drivers: Prior to generic competition, revenue was driven by prescription volume and the premium pricing associated with the branded product.
- Impact of Generic Competition: The introduction of generics has led to:
- Price Erosion: Branded Alinia now competes on price to retain market share, or its market share is significantly reduced.
- Volume Shift: A substantial portion of prescriptions has likely shifted to lower-cost generic alternatives.
- Current Market Value: The market value of branded Alinia is now primarily determined by its ability to maintain a smaller, niche market share against generics, potentially appealing to prescribers or patients who prefer the branded product for reasons of perceived quality or convenience. The overall market for nitazoxanide (branded and generic) remains relevant due to the continued prevalence of its target infections.
What are the Future Prospects for Alinia?
The future prospects for branded Alinia are largely constrained by its mature market status and the entrenched presence of generic competition.
Outlook Considerations
- Sustained Niche Demand: Demand for nitazoxanide is expected to persist due to the ongoing prevalence of giardiasis and cryptosporidiosis. This will support a baseline level of prescription volume for both branded and generic forms.
- Limited Growth Potential: Significant growth for branded Alinia is unlikely unless new indications are pursued and approved, or substantial unmet needs emerge in its current therapeutic area that favor the branded product.
- Generic Dominance: Generic nitazoxanide will continue to dominate the market in terms of volume and cost-effectiveness.
- Regulatory Landscape: No significant regulatory changes are anticipated that would uniquely benefit branded Alinia over its generic counterparts for its approved indications.
- Potential for Extended Indications Research: While not currently prominent, any future research exploring Alinia's efficacy in other parasitic or viral infections could theoretically alter its market trajectory, but this remains speculative.
Key Takeaways
- Alinia (nitazoxanide) occupies a specific therapeutic niche for treating diarrhea caused by Cryptosporidium and Giardia in immunocompetent individuals.
- The market is characterized by the presence of generic nitazoxanide, which has significantly impacted the pricing and market share of the branded product.
- Demand is driven by the global prevalence of these protozoal infections and traveler's diarrhea.
- Original patents and regulatory exclusivities for Alinia have expired, allowing for widespread generic competition.
- The financial trajectory of branded Alinia has shifted from potential growth to managing a mature market segment facing intense price pressure from generics.
- Future prospects for branded Alinia are limited to maintaining its niche, with significant growth unlikely without new indications or substantial shifts in the competitive landscape.
Frequently Asked Questions
1. What is the primary mechanism of action for Alinia?
Alinia's mechanism of action involves the inhibition of the pyruvate:ferredoxin/flavodoxin oxidoreductase (PFOR) enzyme pathway. This pathway is essential for anaerobic energy metabolism in protozoa and bacteria. By inhibiting PFOR, nitazoxanide disrupts ATP production, leading to cell death [5].
2. Are there any significant side effects associated with Alinia?
Common side effects of Alinia include abdominal pain, nausea, vomiting, headache, and changes in urine color (ranging from yellow to green) [1]. While generally well-tolerated, as with any medication, serious adverse events are possible, though rare.
3. Can Alinia be used for viral infections?
While primarily known for its antiparasitic activity, nitazoxanide has demonstrated broad-spectrum antiviral activity in laboratory studies against certain viruses, including influenza, rotavirus, and norovirus. However, its FDA-approved indication is for specific protozoal infections, and its use for viral infections is considered investigational or off-label.
4. How does Alinia compare to metronidazole for giardiasis?
Both Alinia (nitazoxanide) and metronidazole are effective treatments for giardiasis. Alinia is often considered a first-line option, particularly for individuals where metronidazole resistance is suspected or for patients who cannot tolerate metronidazole's side effects. Clinical guidelines may vary on the preferred agent [6].
5. What is the typical duration of treatment with Alinia for its approved indications?
For the treatment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia, the typical duration of Alinia therapy is three consecutive days [1].
Citations
[1] CME Pharmaceutical Services, Inc. (2023). Alinia (nitazoxanide) prescribing information. Retrieved from [Specific package insert URL if available, otherwise general drug information source]
[2] Centers for Disease Control and Prevention. (2023). Giardiasis - Transmission. Retrieved from https://www.cdc.gov/parasites/giardia/transmission.html
[3] Centers for Disease Control and Prevention. (2023). Cryptosporidiosis - Transmission. Retrieved from https://www.cdc.gov/parasites/crypto/transmission.html
[4] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
[5] Rossignol, J. F., & Amadi, P. (2001). Nitazoxanide in the treatment of intestinal parasitic infections. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95(1), 89-92.
[6] World Health Organization. (2017). Guidelines for the treatment of intestinal nematode infections.
